Gene Activation, Apolipoprotein A‐I/High Density Lipoprotein, Atherosclerosis Prevention and Longevity
Author:
Open Access
- 1 August 1997
- journal article
- review article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 81 (2) , 57-64
Abstract
Recent studies in man and human apolipoprotein A‐I transgenic animals emphasize the significance of apolipoprotein A‐I and high density lipoprotein in antiatherogenesis. Several drugs and other compounds, e.g. phenobarbital, gemfibrozil, fenofibrate, prednisone, estrogen and alcohol, induce apolipoprotein A‐I synthesis. They commonly produce serum lipoprotein patterns typical of a low risk of coronary heart disease, and many of them have been found to prevent atherogenesis, reduce coronary heart disease mortality and increase survival. These compounds act against atherosclerosis by using one or several mechanisms that include overexpression of the apolipoprotein A‐I gene with an increase in serum apolipoprotein A‐I and high density lipoprotein and promotion of reverse cholesterol transport, upregulation of the low density lipoprotein receptor gene with a decrease in serum apolipoprotein B and low density lipoprotein, maintenance of endothelial cell function and protection against thrombosis. They have been found to raise high density lipoprotein cholesterol and apolipoprotein A‐I together with a decrease in cholesterol ester transfer protein activity, and to induce hepatic cholesterol 7α‐hydroxylase and cholesterol and bile acid elimination from the body. By raising the activities of apolipoprotein A‐I/ high density lipoprotein‐associated paraoxonase and other antioxidative enzymes, the inducers have the capacity to prevent atherogenesis in arterial walls through inhibition of the oxidative modification of low density lipoprotein. Other antiatherogenic vascular actions of high density lipoprotein include interference with low density lipoprotein aggregation and uptake by endothelial cells, and competition with low density lipoprotein for endothelial‐localized low density lipoprotein receptors. Apolipoprotein A‐I/high density lipoprotein beneficially enhances fibrinolysis, decreases platelet aggregation, increases prostacyclin production and stabilization and prevents atherogenic immune and inflammatory responses. This gene activation or microsomal induction can prevent atherosclerosis and is a basis for tailoring effective new agents and optimal non‐invasive therapy against atherosclerotic vascular disease, to promote health and enhance longevity.Keywords
This publication has 56 references indexed in Scilit:
- A Prospective, Randomized Trial of Phenytoin in Nonepileptic Subjects With Reduced HDL CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Intravenous Injection of Rabbit Apolipoprotein A-I Inhibits the Progression of Atherosclerosis in Cholesterol-Fed RabbitsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effects of Phenytoin on Plasma High‐Density Lipoprotein Cholesterol Levels in Men with Low Levels of High‐Density Lipoprotein CholesterolThe Journal of Clinical Pharmacology, 1995
- Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studiesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Regulation of apolipoprotein A-I gene expression by phenobarbital in the human hepatocarcinoma cell line, Hep3BAtherosclerosis, 1994
- Effects of Simvastatin and Pravastatin on 6β-hydroxycortisol Excretion, a Potential Marker of Cytochrome P-450 3APharmacological Research, 1993
- Hypolipidemic Activity in Rodents of Phenobarbital and Related DerivativesArchiv der Pharmazie, 1990
- Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transportThe American Journal of Cardiology, 1989
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Plasma High‐Density Lipoproteins and Liver Lipids and Proteins in ManActa Medica Scandinavica, 1983